Table 2.
Open in new tab

Association of baseline t-MRI scores with clinical and antibody-based subgroups

t-MRI scores (median, IQR)
Clinical subgroupsDM (n = 32)AsyS (n = 19)Others (n = 8)P-value
Muscle oedema19.07(7.59–40.83)7.77*(0.00–20.37)43.70(28.61–53.14)0.001
Fascial oedema46.56(22.22–79.46)23.33*(10.00–43.33)32.22(5.27–56.38)0.035
Muscle atrophy0.00(0.00–2.22)0.00(0.00–3.33)3.33(0.00–27.91)0.262
Fatty infiltration2.22(0.22–4.44)2.22(0.00–11.11)4.44(0.55–31.88)0.402
Myositis-specific antibody subgroups
MSA-positive DM (n = 19)Antisynthetase (n = 19)MSA-negative DM (n = 12)P-value
Muscle oedema27.41(9.29–47.41)7.77(0.00–20.37)17.97(3.43–37.50)0.037
Fascial oedema44.44(17.78–86.67)23.33(10.00–43.33)55.00(36.94–79.47)0.004
Muscle atrophy2.22(0.00–8.89)0.00(0.00–3.33)0.00(0.00–0.00)0.240
Fatty infiltration2.22(0.00–8.89)2.22(0.00–11.11)0.56(0.00–3.03)0.069
Myositis-associated antibody status
Only MSA+(n = 32)MSA+ and MAA+ (n = 11)No autoantibodies (n = 12)P-value
Muscle oedema22.22(8.15–38.88)1.48(0.00–12.22)20.55(3.42–44.62)0.013
Fascial oedema37.89(14.44–56.30)12.22(0.00–44.44)55.00(27.77–80.27)0.018
Muscle atrophy2.22(0.00–11.66)0.00(0.00–2.22)0.00(0.00–0.00)0.023
Fatty infiltration4.44(0.00–11.94)2.22(0.00–8.89)0.55(0.00–3.05)0.193
t-MRI scores (median, IQR)
Clinical subgroupsDM (n = 32)AsyS (n = 19)Others (n = 8)P-value
Muscle oedema19.07(7.59–40.83)7.77*(0.00–20.37)43.70(28.61–53.14)0.001
Fascial oedema46.56(22.22–79.46)23.33*(10.00–43.33)32.22(5.27–56.38)0.035
Muscle atrophy0.00(0.00–2.22)0.00(0.00–3.33)3.33(0.00–27.91)0.262
Fatty infiltration2.22(0.22–4.44)2.22(0.00–11.11)4.44(0.55–31.88)0.402
Myositis-specific antibody subgroups
MSA-positive DM (n = 19)Antisynthetase (n = 19)MSA-negative DM (n = 12)P-value
Muscle oedema27.41(9.29–47.41)7.77(0.00–20.37)17.97(3.43–37.50)0.037
Fascial oedema44.44(17.78–86.67)23.33(10.00–43.33)55.00(36.94–79.47)0.004
Muscle atrophy2.22(0.00–8.89)0.00(0.00–3.33)0.00(0.00–0.00)0.240
Fatty infiltration2.22(0.00–8.89)2.22(0.00–11.11)0.56(0.00–3.03)0.069
Myositis-associated antibody status
Only MSA+(n = 32)MSA+ and MAA+ (n = 11)No autoantibodies (n = 12)P-value
Muscle oedema22.22(8.15–38.88)1.48(0.00–12.22)20.55(3.42–44.62)0.013
Fascial oedema37.89(14.44–56.30)12.22(0.00–44.44)55.00(27.77–80.27)0.018
Muscle atrophy2.22(0.00–11.66)0.00(0.00–2.22)0.00(0.00–0.00)0.023
Fatty infiltration4.44(0.00–11.94)2.22(0.00–8.89)0.55(0.00–3.05)0.193

AsyS: antisynthetase syndrome; MSA: myositis-specific antibodies; MAA: myositis-associated antibodies; Others, PM and IMNM. Bold text indicates P < 0.05.

Table 2.
Open in new tab

Association of baseline t-MRI scores with clinical and antibody-based subgroups

t-MRI scores (median, IQR)
Clinical subgroupsDM (n = 32)AsyS (n = 19)Others (n = 8)P-value
Muscle oedema19.07(7.59–40.83)7.77*(0.00–20.37)43.70(28.61–53.14)0.001
Fascial oedema46.56(22.22–79.46)23.33*(10.00–43.33)32.22(5.27–56.38)0.035
Muscle atrophy0.00(0.00–2.22)0.00(0.00–3.33)3.33(0.00–27.91)0.262
Fatty infiltration2.22(0.22–4.44)2.22(0.00–11.11)4.44(0.55–31.88)0.402
Myositis-specific antibody subgroups
MSA-positive DM (n = 19)Antisynthetase (n = 19)MSA-negative DM (n = 12)P-value
Muscle oedema27.41(9.29–47.41)7.77(0.00–20.37)17.97(3.43–37.50)0.037
Fascial oedema44.44(17.78–86.67)23.33(10.00–43.33)55.00(36.94–79.47)0.004
Muscle atrophy2.22(0.00–8.89)0.00(0.00–3.33)0.00(0.00–0.00)0.240
Fatty infiltration2.22(0.00–8.89)2.22(0.00–11.11)0.56(0.00–3.03)0.069
Myositis-associated antibody status
Only MSA+(n = 32)MSA+ and MAA+ (n = 11)No autoantibodies (n = 12)P-value
Muscle oedema22.22(8.15–38.88)1.48(0.00–12.22)20.55(3.42–44.62)0.013
Fascial oedema37.89(14.44–56.30)12.22(0.00–44.44)55.00(27.77–80.27)0.018
Muscle atrophy2.22(0.00–11.66)0.00(0.00–2.22)0.00(0.00–0.00)0.023
Fatty infiltration4.44(0.00–11.94)2.22(0.00–8.89)0.55(0.00–3.05)0.193
t-MRI scores (median, IQR)
Clinical subgroupsDM (n = 32)AsyS (n = 19)Others (n = 8)P-value
Muscle oedema19.07(7.59–40.83)7.77*(0.00–20.37)43.70(28.61–53.14)0.001
Fascial oedema46.56(22.22–79.46)23.33*(10.00–43.33)32.22(5.27–56.38)0.035
Muscle atrophy0.00(0.00–2.22)0.00(0.00–3.33)3.33(0.00–27.91)0.262
Fatty infiltration2.22(0.22–4.44)2.22(0.00–11.11)4.44(0.55–31.88)0.402
Myositis-specific antibody subgroups
MSA-positive DM (n = 19)Antisynthetase (n = 19)MSA-negative DM (n = 12)P-value
Muscle oedema27.41(9.29–47.41)7.77(0.00–20.37)17.97(3.43–37.50)0.037
Fascial oedema44.44(17.78–86.67)23.33(10.00–43.33)55.00(36.94–79.47)0.004
Muscle atrophy2.22(0.00–8.89)0.00(0.00–3.33)0.00(0.00–0.00)0.240
Fatty infiltration2.22(0.00–8.89)2.22(0.00–11.11)0.56(0.00–3.03)0.069
Myositis-associated antibody status
Only MSA+(n = 32)MSA+ and MAA+ (n = 11)No autoantibodies (n = 12)P-value
Muscle oedema22.22(8.15–38.88)1.48(0.00–12.22)20.55(3.42–44.62)0.013
Fascial oedema37.89(14.44–56.30)12.22(0.00–44.44)55.00(27.77–80.27)0.018
Muscle atrophy2.22(0.00–11.66)0.00(0.00–2.22)0.00(0.00–0.00)0.023
Fatty infiltration4.44(0.00–11.94)2.22(0.00–8.89)0.55(0.00–3.05)0.193

AsyS: antisynthetase syndrome; MSA: myositis-specific antibodies; MAA: myositis-associated antibodies; Others, PM and IMNM. Bold text indicates P < 0.05.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close